BACKGROUND AND OBJECTIVE: Gemcitabine is widely used to treat non-small cell lung cancer (NSCLC). The aim of this study was to assess the pharmacogenomic effects of the entire gemcitabine metabolic pathway, we genotyped single nucleotide polymorphisms (SNPs) within the 17 pathway genes using DNA samples from patients with NSCLC treated with gemcitabine to determine the effect of genetic variants within gemcitabine pathway genes on overall survival (OS) of patients with NSCLC after treatment of gemcitabine. METHODS: Eight of the 17 pathway genes were resequenced with DNA samples from Coriell lymphoblastoid cell lines (LCLs) using Sanger sequencing for all exons, exon-intron junctions, and 5'-, 3'-UTRs. A total of 107 tagging SNPs were selected on the basis of the resequencing data for the eight genes and on HapMap data for the remaining nine genes, followed by successful genotyping of 394 NSCLC patient DNA samples. Association of SNPs/haplotypes with OS was performed using the Cox regression model, followed by functional studies performed with LCLs and NSCLC cell lines. RESULTS: Five SNPs in four genes (CDA, NT5C2, RRM1, and SLC29A1) showed associations with OS of those patients with NSCLC, as well as nine haplotypes in four genes (RRM1, RRM2, SLC28A3, and SLC29A1) with a P value of less than 0.05. Genotype imputation using the LCLs was performed for a region of 200 kb surrounding those SNPs, followed by association studies with gemcitabine cytotoxicity. Functional studies demonstrated that downregulation of SLC29A1, NT5C2, and RRM1 in NSCLC cell lines altered cell susceptibility to gemcitabine. CONCLUSION: These studies help in identifying biomarkers to predict gemcitabine response in NSCLC, a step toward the individualized chemotherapy of lung cancer.
BACKGROUND AND OBJECTIVE:Gemcitabine is widely used to treat non-small cell lung cancer (NSCLC). The aim of this study was to assess the pharmacogenomic effects of the entire gemcitabine metabolic pathway, we genotyped single nucleotide polymorphisms (SNPs) within the 17 pathway genes using DNA samples from patients with NSCLC treated with gemcitabine to determine the effect of genetic variants within gemcitabine pathway genes on overall survival (OS) of patients with NSCLC after treatment of gemcitabine. METHODS: Eight of the 17 pathway genes were resequenced with DNA samples from Coriell lymphoblastoid cell lines (LCLs) using Sanger sequencing for all exons, exon-intron junctions, and 5'-, 3'-UTRs. A total of 107 tagging SNPs were selected on the basis of the resequencing data for the eight genes and on HapMap data for the remaining nine genes, followed by successful genotyping of 394 NSCLCpatient DNA samples. Association of SNPs/haplotypes with OS was performed using the Cox regression model, followed by functional studies performed with LCLs and NSCLC cell lines. RESULTS: Five SNPs in four genes (CDA, NT5C2, RRM1, and SLC29A1) showed associations with OS of those patients with NSCLC, as well as nine haplotypes in four genes (RRM1, RRM2, SLC28A3, and SLC29A1) with a P value of less than 0.05. Genotype imputation using the LCLs was performed for a region of 200 kb surrounding those SNPs, followed by association studies with gemcitabinecytotoxicity. Functional studies demonstrated that downregulation of SLC29A1, NT5C2, and RRM1 in NSCLC cell lines altered cell susceptibility to gemcitabine. CONCLUSION: These studies help in identifying biomarkers to predict gemcitabine response in NSCLC, a step toward the individualized chemotherapy of lung cancer.
Authors: Daniel J Schaid; Charles M Rowland; David E Tines; Robert M Jacobson; Gregory A Poland Journal: Am J Hum Genet Date: 2001-12-27 Impact factor: 11.025
Authors: G V Scagliotti; F De Marinis; M Rinaldi; L Crinò; C Gridelli; S Ricci; E Matano; C Boni; M Marangolo; G Failla; G Altavilla; V Adamo; A Ceribelli; M Clerici; F Di Costanzo; L Frontini; M Tonato Journal: J Clin Oncol Date: 2002-11-01 Impact factor: 44.544
Authors: A B Sandler; J Nemunaitis; C Denham; J von Pawel; Y Cormier; U Gatzemeier; K Mattson; C Manegold; M C Palmer; A Gregor; B Nguyen; C Niyikiza; L H Einhorn Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Frank Fossella; Jose R Pereira; Joachim von Pawel; Anna Pluzanska; Vera Gorbounova; Eckhard Kaukel; Karin V Mattson; Rodryg Ramlau; Aleksandra Szczesna; Panagiotis Fidias; Michael Millward; Chandra P Belani Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Stephen A Baldwin; Paul R Beal; Sylvia Y M Yao; Anne E King; Carol E Cass; James D Young Journal: Pflugers Arch Date: 2003-06-28 Impact factor: 3.657
Authors: Jennifer H Gray; Lara M Mangravite; Ryan P Owen; Thomas J Urban; Wendy Chan; Elaine J Carlson; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Douglas Stryke; Thomas E Ferrin; Kathleen M Giacomini Journal: Mol Pharmacol Date: 2004-03 Impact factor: 4.436